Inspira Technologies Announces Successful 97.3% Accuracy in HYLA™ Blood Sensor Testing, Paving Way for FDA Submission
Reuters
Sep 11
Inspira Technologies Announces Successful 97.3% Accuracy in HYLA™ Blood Sensor Testing, Paving Way for FDA Submission
Inspira Technologies OXY B.H.N. Ltd. has announced pivotal results from performance testing of its HYLA™ Blood Sensor, achieving an accuracy rate of 97.35% in comparison to standard blood gas analyzers. These results mark a significant advancement from the initial clinical study data released in March 2025. The HYLA sensor, which is designed for continuous, non-invasive monitoring of blood parameters, aims to provide real-time alerts to medical teams, potentially enhancing decision-making in critical care settings. The results will support Inspira's upcoming submission for U.S. Food and Drug Administration clearance. The HYLA sensor is developed both as a standalone device and for integration with Inspira's ART device line, targeting a broad market that includes various medical procedures such as cardiopulmonary bypass and dialysis.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inspira Technologies OXY BHN Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-086686), on September 11, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.